Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score:57

Nature

Volume 3 Issue 1, January 2022 - 2 days

Mashup Score:57

Volume 3 Issue 1, January...

Mayo Clinic Center for Individualized Medicine researchers may have discovered a genomic signature to predict which patients with mesothelioma could...

SITC 2021 Hannah E. Dzimitrowicz, MD, of Duke Cancer Center, discusses study results showing that in patients with melanoma and renal cell cancer receiving...

Chemotherapy with anti PD-1/PD-L1 antibodies has become the standard of care for patients with metastatic non-small cell lung cancer (mNSCLC). Using...

Prior durvalumab (anti-PD-L1 agent) studies in platinum-refractory metastatic urothelial carcinoma evaluated a dose of 10 mg/kg administered every...

Dual co-stimulation by CD28 and 41BB contributes importantly to physiological immune responses, highlighting the desirability of harnessing these pathways to potentiate CAR T cell immunotherapy....

Once an irAE is identified, proper multidisciplinary management is...

Key Points. Pola-BR is an efficacious treatment for relapsed/refractory DLBCL in SCT-ineligible patients, as briding to CAR T and after CAR T failureNumber of...

We assessed minimal residual disease (MRD) detection and B-cell aplasia after tisagenlecleucel therapy for acute lymphoblastic leukemia (ALL) to define biomarkers predictive of relapse...

Patients with diffuse large B-cell lymphoma who have refractory or relapsed disease following first line treatment have a poor prognosis when treated...